Medicus Pharma shares surge 10.53% intraday after filing FDA National Priority Voucher Application for non-invasive basal cell carcinoma treatment.

Medicus Pharma surged 10.53% intraday following the announcement of filing an FDA Commissioner's National Priority Voucher (CNPV) application for SKNJCT-003, a non-invasive treatment for basal cell carcinoma. This regulatory milestone, aimed at incentivizing therapies for rare diseases, signaled progress in the company’s pipeline and enhanced investor confidence in its commercial potential. The move aligns with recent strategic advancements, including expanded clinical trials and acquisitions, but the immediate catalyst was the CNPV submission, which underscores the drug’s eligibility for expedited regulatory pathways and market exclusivity incentives.